AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China


Source: wsj.com wsj.com

Key Topics in this News Article:

News Snapshot:

AstraZeneca PLC has agreed to have a Chinese drugmaker produce hundreds of millions of doses of its experimental Covid-19 vaccine for use in China if it is approved by regulators there, a deal that expands China’s access to potential vaccine options. Shenzhen Kangtai Biological Products Co. will be able to manufacture at least 100 million doses of AstraZeneca’s vaccine by year’s end, and at least 200 million by the end of 2021, according to statements by both companies Thursday. ...